← Back to Clinical Trials
Recruiting NCT06916195

NCT06916195 Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06916195
Status Recruiting
Phase
Sponsor MSD Italia S.r.l.
Condition Cytomegalovirus Infection
Study Type OBSERVATIONAL
Enrollment 230 participants
Start Date 2025-05-09
Primary Completion 2026-04-30

Eligibility & Interventions

Sex All sexes
Min Age 0 Years
Max Age 18 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 230 participants in total. It began in 2025-05-09 with a primary completion date of 2026-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This observational retrospective analysis will provide useful information for clinicians and payers, and local guidelines committee members, to improve the understanding of Cytomegalovirus clinical and economic burden and clinical management of pediatric patients undergoing allogeneic Hematopoietic Stem Cells Transplantation in Italy.

Eligibility Criteria

Inclusion Criteria: * Patients from birth to less than 18 years of age (at the moment of the allogeneic HSCT); * Patients who received allogeneic HSCT between January 2018 and June 2020; * Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF), if applicable. Exclusion Criteria: * Letermovir use at any time

Contact & Investigator

Central Contact

Antonia Maffucci

✉ info.studiclinici@opisresearch.com

📞 +39 03626331

Frequently Asked Questions

Who can join the NCT06916195 clinical trial?

This trial is open to participants of all sexes, aged 0 Years or older, up to 18 Years, studying Cytomegalovirus Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06916195 currently recruiting?

Yes, NCT06916195 is actively recruiting participants. Contact the research team at info.studiclinici@opisresearch.com for enrollment information.

Where is the NCT06916195 trial being conducted?

This trial is being conducted at Genova, Italy, Monza, Italy, Padova, Italy, Roma, Italy and 1 additional location.

Who is sponsoring the NCT06916195 clinical trial?

NCT06916195 is sponsored by MSD Italia S.r.l.. The trial plans to enroll 230 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology